作者
Jeffrey S. Weber,Michele Del Vecchio,Mario Mandalà,Helen Gogas,Ana Arance,Stéphane Dalle,C. Lance Cowey,Michael Schenker,Jean‐Jacques Grob,Vanna Chiarion‐Sileni,Iván Márquez‐Rodas,Marcus O. Butler,Anna Maria Di Giacomo,Luis de la Cruz‐Merino,Petr Arenberger,Victoria Atkinson,Andrew F. Hill,Leslie A. Fecher,Michael Millward,Nikhil I. Khushalani,Paola Queirolo,Georgina V. Long,Maurice Lobo,Margarita Askelson,Paolo A. Ascierto,James Larkin
摘要
In phase III CheckMate 238, adjuvant nivolumab significantly improved recurrence-free survival compared with ipilimumab in patients with resected stage IIIB-C/IV melanoma without a significant difference in overall survival (OS). Here, we investigate progression-free survival (PFS) and OS after postrecurrence systemic therapy.
毛豆
cocolu
SYLH
穿裤子的云
MchemG
藤椒辣鱼
香蕉谷芹
ceeray23
Chillichee
shhoing
duanhuiyuan
幽壑之潜蛟
pcr163
sutharsons
yyds
Magali
IIIIIllllIIII
jyy
marco
剑指东方是为谁
皖公网安备34019202002308
